Compare TCX & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCX | ANIK |
|---|---|---|
| Founded | 1992 | 1983 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.9M | 191.4M |
| IPO Year | 2005 | 1996 |
| Metric | TCX | ANIK |
|---|---|---|
| Price | $15.96 | $12.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 20.0K | ★ 99.2K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $362,275,000.00 | $112,819,000.00 |
| Revenue This Year | N/A | $5.98 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $15.18 | $7.90 |
| 52 Week High | $25.17 | $16.24 |
| Indicator | TCX | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 31.25 |
| Support Level | $15.43 | $9.43 |
| Resistance Level | $18.63 | $15.01 |
| Average True Range (ATR) | 0.75 | 0.80 |
| MACD | -0.04 | -0.28 |
| Stochastic Oscillator | 26.53 | 2.22 |
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. The company generates key revenue from Canada and USA.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.